Find and Pitch Jounalists, Get Your Story Covered

Tags: B Corp ESG certification

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 8 days ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 6 months ago A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu - 7 months ago CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning - 8 months ago Year in Review: Follicular Lymphoma - 10 months ago
2	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Priority Review for Durvalumab to Treat Small Cell Lung Cancer - about 1 month ago
3	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 3 months ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 3 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 8 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - 8 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 9 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 9 months ago Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma - 9 months ago Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma - 9 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 9 months ago Positive Results for Odronextamab in Relapsed/Refractory DLBCL - 9 months ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 3 months ago Brentuximab Vedotin Shows 37% Reduction in Risk of Death for DLBCL - 3 months ago Study: Mutation Found to Make Follicular Lymphoma More Susceptible to Experimental Drug - 6 months ago Study: Lymphoma Patients Recover Longer for Pneumonia - 6 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 7 months ago Neoadjuvant Chemotherapy Could Help Patients With Breast Cancer Skip Regional Nodal Irradiation - 8 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 10 months ago
5	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 3 months ago FDA Approves First CAR-T for Chronic Lymphocytic Leukemia - 6 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 9 months ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - 9 months ago Non-Covalent BTK Inhibitor Approved for CLL - 10 months ago
6	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Managing Adverse Event Profiles for Three Bispecific Antibodies Approved for Lymphoma - 6 months ago Patients With CLL Present Heterogeneously - 7 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - 8 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - 9 months ago
7	Erin Hunter, Assistant Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	Mosunetuzumab Led to Durable Complete Response in Majority of Patients with Lymphoma During Follow-Up Study - 9 months ago More than 80% of Patients with Diffuse Large B-cell Lymphoma Responded to Novel Therapeutic, according to the Results of a Preclinical Trial - 9 months ago FDA Updates Label for Axicabtagene Ciloleucel for R/R LBCL Following Positive Long-Term Survival Data - 9 months ago Hispanic Patients with Philadelphia (Ph)-Like B-cell Acute Lymphoblastic Leukemia Continue to Experience Poor Outcomes, According to Expert - 9 months ago Drug Sequence Might Not Significantly Impact Survival Outcomes of Patients with Lymphoma - 9 months ago Golidocitinib Demonstrates Significant Survival Benefits For Patients with Peripheral T-cell Lymphoma - 9 months ago New Update Changes Terminology for Some Cutaneous Lymphomas - about 1 year ago
8	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	STAT+: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case - 10 months ago STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - 10 months ago
9	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	FDA Approves Lilly's Jaypirca for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma - 10 months ago FDA Grants Priority Review to Expand Indication for Bristol Myers Squibb’s Breyanzi in CLL, SLL - 10 months ago
10	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - 10 months ago

Journalists covering Diffuse Large B Cell Lymphoma